Effect of salivary secretion on the onset of reflux esophagitis

Effect of salivary secretion on the onset of PPI-resistant severe reflux esophagitis - Salivary secretion and refractory reflux esophagitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040806

Enrollment

Registered

2020-06-19

Start date

2020-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patientes who have had standard-dose oral PPI therapy over 8 weeks 2. Patients who have been diagnosed with severe reflux esophagitis before PPI therapy 3. Pylori negative patients 4. Patients who have not been diagnosed with gastrotic mucosal atrophy (C-1 or C-2) 5. Patiens who have endoscopic hernia bigger than 2cm

Exclusion criteria

Exclusion criteria: except as mentioned above

Design outcomes

Primary

Measure	Time frame
Volume of stimulated saliva pH of stimulated saliva acid-buffering capacity salivary epidermal growth factor (EGF) concentration	—

Countries

Japan

Contacts

Public ContactTomohide Tanabe

Nippon Medical School Department of Gastroenterology

tanabe@nms.ac.jp03-3822-2131

Outcome results